Loading…
Sectoral / Thematic · UTI Mutual Fund · AMFI code 100806UTI - Healthcare Fund
Disclosed for 95 months, Jul 2017 to Sep 2026.
Portfolio value
₹316 Cr
down ₹10 Cr vs Jul 2017
- Stocks held
- 25
- down 2 vs Jul 2017
- Top 10 weight
- 59.4%
- of the portfolio in its ten largest
- Largest position
- 10.1%
UTI - Healthcare Fund is an active equity fund in the Sectoral / Thematic category from UTI Mutual Fund. In August 2017 it disclosed 25 stocks worth ₹316 Cr, down ₹10 Cr from Jul 2017. Its largest positions were Aurobindo Pharma Limited (10.1%), Sun Pharmaceutical Industries Limited (7.5%), Dr. Reddy's Laboratories Limited (7.1%); the ten largest together made up 59.4% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 69.7% of its equity. Cash and debt stood at 5.0%. Compared with Jul 2017 the fund entered 0 new stocks and exited 2.
Against 229 other Sectoral / Thematic funds
Concentration
82%
Top-10 weight is higher than 82% of peers
Breadth
8%
Holds more stocks than 8% of peers
Cash
71%
Holds more cash than 71% of peers
What these mean: concentration · cash
Holdings in August 2017
Download CSVEvery line the fund disclosed, with the change against Jul 2017. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Aurobindo Pharma Limited | 10.12% | up 0.40 pts | ₹31.9 Cr | up ₹29 L | Added |
| Sun Pharmaceutical Industries Limited | 7.49% | down 3.81 pts | ₹23.6 Cr | down ₹13.2 Cr | Trimmed |
| Dr. Reddy's Laboratories Limited | 7.10% | up 5.65 pts | ₹22.4 Cr | up ₹17.7 Cr | Added |
| Zydus Lifesciences Limited | 5.51% | up 2.16 pts | ₹17.4 Cr | up ₹6.5 Cr | Added |
| Dishman Carbogen Amcis Limited | 5.45% | up 0.17 pts | ₹17.2 Cr | — | Held |
| Strides Pharma Science Limited | 5.39% | down 0.72 pts | ₹17 Cr | down ₹2.9 Cr | Trimmed |
| Torrent Pharmaceuticals Limited | 5.12% | down 0.12 pts | ₹16.2 Cr | down ₹91 L | Trimmed |
| Cipla Limited | 5.08% | up 0.26 pts | ₹16.1 Cr | up ₹33 L | Added |
| Cash, TREPS & receivables | 4.96% | down 2.31 pts | ₹15.7 Cr | down ₹8 Cr | Trimmed |
| Piramal Enterprises Limited | 4.39% | down 0.24 pts | ₹13.9 Cr | down ₹1.2 Cr | Trimmed |
| Pfizer Limited | 3.72% | up 0.19 pts | ₹11.8 Cr | up ₹23 L | Added |
| Alkem Laboratories Limited | 3.60% | up 0.05 pts | ₹11.4 Cr | down ₹20 L | Trimmed |
| Natco Pharma Limited | 3.42% | up 0.56 pts | ₹10.8 Cr | up ₹1.5 Cr | Added |
| Sanofi India Limited | 3.39% | down 0.10 pts | ₹10.7 Cr | down ₹67 L | Trimmed |
| Max India Limited | 3.28% | down 0.09 pts | ₹10.4 Cr | down ₹63 L | Trimmed |
| Narayana Hrudayalaya Limited | 3.14% | up 0.05 pts | ₹9.9 Cr | down ₹15 L | Trimmed |
| Sun Pharma Advanced Research Company Limited | 2.98% | up 0.15 pts | ₹9.4 Cr | up ₹19 L | Added |
| FDC Limited | 2.60% | down 0.13 pts | ₹8.2 Cr | down ₹68 L | Trimmed |
| IPCA Laboratories Limited | 2.25% | up 0.10 pts | ₹7.1 Cr | up ₹9 L | Added |
| Apollo Hospitals Enterprise Limited | 2.20% | down 0.28 pts | ₹7 Cr | down ₹1.1 Cr | Trimmed |
| Biocon Limited | 2.12% | down 0.23 pts | ₹6.7 Cr | down ₹95 L | Trimmed |
| Dr. Lal Path Labs Limited | 2.03% | up 0.01 pts | ₹6.4 Cr | down ₹18 L | Trimmed |
| Unichem Laboratories Limited | 1.65% | down 0.09 pts | ₹5.2 Cr | down ₹45 L | Trimmed |
| Indoco Remedies Limited | 1.29% | down <0.01 pts | ₹4.1 Cr | down ₹13 L | Trimmed |
| Shilpa Medicare Limited | 0.88% | down 0.06 pts | ₹2.8 Cr | down ₹28 L | Trimmed |
| Ajanta Pharma Limited | 0.83% | down 0.11 pts | ₹2.6 Cr | down ₹45 L | Trimmed |
What changed, Jul 2017 to Aug 2017
New New positions (0)
None.
Exited Exited (2)
- Lupin Limitedwas 0.8% · ₹2.5 Cr
- Divi's Laboratories Limitedwas 0.7% · ₹2.2 Cr
Added Biggest additions
- Dr. Reddy's Laboratories Limitedup ₹17.7 Cr (+5.65% pts)
- Zydus Lifesciences Limitedup ₹6.5 Cr (+2.16% pts)
- Natco Pharma Limitedup ₹1.5 Cr (+0.56% pts)
- Cipla Limited
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Jul 2017, the weight rose most in Pharmaceuticals & Biotechnology (+2.1 pts), and fell most in Pharmaceuticals (−1.1 pts) and Healthcare Services (−0.6 pts).
- Pharmaceuticals & Biotechnology67.6% → 69.7%+2.1 pts
- Pharmaceuticals15.5% → 14.5%−1.1 pts
- Healthcare Services11.8% → 11.2%−0.6 pts
- Finance5.0% → 4.6%−0.4 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Jul 2017 | Aug 2017 |
|---|---|---|
| Pharmaceuticals & Biotechnology | 67.6% | 69.7% |
| Pharmaceuticals | 15.5% | 14.5% |
| Healthcare Services | 11.8% | 11.2% |
| Finance | 5.0% | 4.6% |
Allocation in Aug 2017change vs Jul 2017
- Pharmaceuticals & Biotechnology (16)69.7%▲ 2.1 pts
- Pharmaceuticals (4)14.5%▼ 1.1 pts
- Healthcare Services (4)11.2%▼ 0.6 pts
- Finance (1)4.6%▼ 0.4 pts
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Aug 2017
5.0%
▼ 2.3 pts vs Jul 2017
- Cash alone
- 5.0%
- cash and net receivables
- A year earlier
- —
- no disclosure
- Last 12 months
- 5.0% – 7.3%
- lowest to highest · record 7.3% in Jul 2017
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.